The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics of ponatinib (PON) therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) patients (pts) in real-world (RW) clinical practice compared to the PACE trial.
 
Michael J. Mauro
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Speakers' Bureau - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis
 
Lisa McGarry
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Mo Yang
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Stephanie Lustgarten
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Hui Huang
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD